Receptor-based dosing optimization of erythropoietin in juvenile sheep after phlebotomy

Drug Metabolism and Disposition

Volumn 39, Issue 7, 2011, Pages 1214-1220

  Rosebraugh, Matthew ^a   Widness, John A ^a   Veng Pedersen, Peter ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; RECOMBINANT ERYTHROPOIETIN;

ANEMIA; ANIMAL EXPERIMENT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; ERYTHROPOIETIN BLOOD LEVEL; HEMOGLOBIN SYNTHESIS; JUVENILE ANIMAL; NONHUMAN; OPTIMAL DRUG DOSE; PHARMACODYNAMICS; PHLEBOTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SHEEP; SIMULATION;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; PHLEBOTOMY; SHEEP;

ANIMALIA; OVIS ARIES;

EID: 79959405544     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.110.036855     Document Type: Article

References (43)

1. Al-Huniti NH, Widness JA, Schmidt RL, and Veng-Pedersen P (2004) Pharmacokinetic/pharmacodynamic analysis of paradoxal regulation of erythropoietin production in acute anemia. J Pharmacol Exp Ther 310:202-208. (Pubitemid 38812712)
2. Becker V, Schilling M, Bachmann J, Baumann U, Raue A, Maiwald T, Timmer J, and Klingmüller U (2010) Covering a broad dynamic range: information processing at the erythropoietin receptor. Science 328:1404-1408.
3. Beguin Y, Clemons GK, Pootrakul P, and Fillet G (1993) Quantitative assessment of erythropoiesis and functional classification of anemia based on measurements of serum transferrin receptor and erythropoietin. Blood 81:1067-1076. (Pubitemid 23054847)
4. Blick M, Sherwin SA, Rosenblum M, and Gutterman J (1987) Phase I study of recombinant tumor necrosis factor in cancer patients. Cancer Res 47:2986-2989. (Pubitemid 17113448)
5. Carlini RG, Alonzo EJ, Dominguez J, Blanca I, Weisinger JR, Rothstein M, and Bellorin-Font E (1999) Effect of recombinant human erythropoietin on endothelial cell apoptosis. Kidney Int 55:546-553. (Pubitemid 29082880)
6. Casadevall N (1995) Cellular mechanism of resistance to erythropoietin. Nephrol Dial Transplant 10 (Suppl 6):27-30.
7. Cazzola M, Guarnone R, Cerani P, Centenara E, Rovati A, and Beguin Y (1998) Red blood cell precursor mass as an independent determinant of serum erythropoietin level. Blood 91:2139-2145. (Pubitemid 28185519)
8. Chapel SH, Veng-Pedersen P, Schmidt RL, and Widness JA (2000) A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharmacol Exp Ther 295:346-351.
9. Chapel SH, Veng-Pedersen P, Schmidt RL, and Widness JA (2001) Receptor-based model accounts for phlebotomy-induced changes in erythropoietin pharmacokinetics. Exp Hematol 29:425-431. (Pubitemid 32297667)
10. Freise KJ, Widness JA, Schmidt RL, and Veng-Pedersen P (2007) Pharmacodynamic analysis of time-variant cellular disposition: reticulocyte disposition changes in phlebotomized sheep. J Pharmacokinet Pharmacodyn 34:519-547. (Pubitemid 47038126)
11. Freise KJ, Widness JA, and Veng-Pedersen P (2010) Erythropoietic response to endogenous erythropoietin in premature very low birth weight infants. J Pharmacol Exp Ther 332:229-237.
12. Fukuda MN, Sasaki H, Lopez L, and Fukuda M (1989) Survival of recombinant erythropoietin in the circulation: the role of carbohydrates. Blood 73:84-89. (Pubitemid 19040958)
13. Jelkmann W (2002) The enigma of the metabolic fate of circulating erythropoietin (Epo) in view of the pharmacokinetics of the recombinant drugs rhEpo and NESP. Eur J Haematol 69:265-274.
14. Jensen JD, Madsen JK, Jensen LW, and Pedersen EB (1994) Reduced production, absorption, and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 5:177-185. (Pubitemid 24977073)
15. Juul SE, Ledbetter DJ, Joyce AE, Dame C, Christensen RD, Zhao Y, and DeMarco V (2001) Erythropoietin acts as a trophic factor in neonatal rat intestine. Gut 49:182-189. (Pubitemid 32675109)
16. Juul SE, Yachnis AT, and Christensen RD (1998) Tissue distribution of erythropoietin and erythropoietin receptor in the developing human fetus. Early Hum Dev 52:235-249. (Pubitemid 28548695)
17. Kampf D, Eckardt KU, Fischer HC, Schmalisch C, Ehmer B, and Schostak M (1992) Pharmacokinetics of recombinant human erythropoietin in dialysis patients after single and multiple subcutaneous administrations. Nephron 61:393-398.
18. Kinoshita H, Ohishi N, Kato M, Tokura S, and Okazaki A (1992) Pharmacokinetics and distribution of recombinant erythropoietin in rats. Arzneimittelforschung 42:174-178.
19. Krzyzanski W and Perez-Ruixo JJ (2007) An assessment of recombinant human erythropoietin effect on reticulocyte production rate and lifespan distribution in healthy subjects. Pharm Res 24:758-772. (Pubitemid 46411964)
20. Levy G (1994) Pharmacologic target-mediated drug disposition. Clin Pharmacol Ther 56:248-252.
21. Mager DE and Jusko WJ (2001) General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn 28:507-532. (Pubitemid 34289541)
22. Mager DE, Woo S, and Jusko WJ (2009) Scaling pharmacodynamics from in vitro and preclinical animal studies to humans. Drug Metab Pharmacokinet 24:16-24.
23. Mock DM, Lankford GL, Burmeister LF, and Strauss RG (1997) Circulating red cell volume and red cell survival can be accurately determined in sheep using the [14C]cyanate label. Pediatr Res 41:916-921. (Pubitemid 27220586)
24. Nalbant D, Saleh M, Goldman FD, Widness JA, and Veng-Pedersen P (2010) Evidence of receptor-mediated elimination of erythropoietin by analysis of erythropoietin receptor mRNA expression in bone marrow and erythropoietin clearance during anemia. J Pharmacol Exp Ther 333:528-532.
25. Nelder JA and Mead R (1965) A simplex-method for function minimization. Comput J 7:308-313.
26. Nielsen OJ, Egfjord M, and Hirth P (1990) The metabolism of recombinant erythropoietin in the isolated perfused rat liver. Liver 10:343-349.
27. Ohls RK, Veerman MW, and Christensen RD (1996) Pharmacokinetics and effectiveness of recombinant erythropoietin administered to preterm infants by continuous infusion in total parenteral nutrition solution. J Pediatr 128:518-523. (Pubitemid 26114090)
28. Ohlsson A and Aher SM (2006) Early erythropoietin for preventing red blood cell transfusion in preterm and/or low birth weight infants. Cochrane Database Syst Rev 3:CD004863.
29. Rizzo JD, Brouwers M, Hurley P, Seidenfeld J, Arcasoy MO, Spivak JL, Bennett CL, Bohlius J, Evanchuk D, Goode MJ, et al. (2010) American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. J Clin Oncol 28:4996-5010.
30. Salmonson T, Danielson BG, Grahnén A, and Wikström B (1990) Pharmacokinetics of intravenous recombinant human erythropoietin in patients with chronic renal failure. J Intern Med 228:53-57. (Pubitemid 20221940)
31. Sans T, Joven J, Vilella E, Masdeu G, and Farrè M (2000) Pharmacokinetics of several subcutaneous doses of erythropoietin: potential implications for blood transfusion. Clin Exp Pharmacol Physiol 27:179-184. (Pubitemid 30158930)
32. Sawyer ST, Krantz SB, and Goldwasser E (1987) Binding and receptor-mediated endocytosis of erythropoietin in Friend virus-infected erythroid cells. J Biol Chem 262:5554-5562.
33. Shepherd VL (1989) Intracellular pathways and mechanisms of sorting in receptor-mediated endocytosis. Trends Pharmacol Sci 10:458-462.
34. Spivak JL and Hogans BB (1989) The in vivo metabolism of recombinant human erythropoietin in the rat. Blood 73:90-99. (Pubitemid 19040959)
35. Till AE, Gomez HJ, Hichens M, Bolognese JA, McNabb WR, Brooks BA, Noormohamed F, and Lant AF (1984) Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers. Biopharm Drug Dispos 5:273-280. (Pubitemid 14073513)
36. Pedersen PV (1977) Curve fitting and modeling in pharmacokinetics and some practical experiences with NONLIN and a new program FUNFIT. J Pharmacokinet Biopharm 5:513-531.
37. Veng-Pedersen P, Chapel S, Al-Huniti NH, Schmidt RL, Sedars EM, Hohl RJ, and Widness JA (2004) Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation. Biopharm Drug Dispos 25:149-156. (Pubitemid 38765288)
38. Veng-Pedersen P, Chapel S, Schmidt RL, Al-Huniti NH, Cook RT, and Widness JA (2002) An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia. Pharm Res 19:1630-1635. (Pubitemid 35305514)
39. Veng-Pedersen P, Widness JA, Pereira LM, Schmidt RL, and Lowe LS (1999) A comparison of nonlinear pharmacokinetics of erythropoietin in sheep and humans. Biopharm Drug Dispos 20:217-223. (Pubitemid 29363908)
40. Widness JA, Schmidt RL, Veng-Pedersen P, Modi NB, and Sawyer ST (1992) A sensitive and specific erythropoietin immunoprecipitation assay: application to pharmacokinetic studies. J Lab Clin Med 119:285-294.
41. Widness JA, Veng-Pedersen P, Peters C, Pereira LM, Schmidt RL, and Lowe LS (1996) Erythropoietin pharmacokinetics in premature infants: developmental, nonlinearity, and treatment effects. J Appl Physiol 80:140-148. (Pubitemid 26034856)
42. Woo S, Krzyzanski W, and Jusko WJ (2007) Target-mediated pharmacokinetic and pharmacodynamic model of recombinant human erythropoietin (rHuEPO). J Pharmacokinet Pharmacodyn 34:849-868. (Pubitemid 350165278)
43. Yamaji R, Okada T, Moriya M, Naito M, Tsuruo T, Miyatake K, and Nakano Y (1996) Brain capillary endothelial cells express two forms of erythropoietin receptor mRNA. Eur J Biochem 239:494-500. (Pubitemid 26246558)